PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.04
D/E less than half of CRVO's 0.61. Charlie Munger would verify if this conservative approach provides competitive advantages.
9.55
Net debt while CRVO maintains net cash position. John Neff would demand higher returns to justify the additional leverage risk.
No Data
No Data available this quarter, please select a different quarter.
10.44
Current ratio 1.25-1.5x CRVO's 9.36. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.